After having hosted DexCom management, Jefferies analyst Matthew Taylor notes that the company discussed data supports CGM use to minimize complications and save costs and CMS having recently expanded coverage to the basal-only patients, adding 3M-4M U.S. covered lives, or "roughly double" the prior state. Scale will fuel margin expansion as G7 ramps, said the firm, which continues to like the shares and reiterates a Buy rating and $150 price target on stock, adding that it views the company’s Q1 report as one that can be a catalyst.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DXCM:
- DexCom announces expanded coverage for G6 CGM System in Manitoba
- DexCom has no material exposure to developments at Silicon Valley Bank
- DexCom pullback on Abbott news a buying opportunity, says Jefferies
- BofA says buy DexCom on weakness after Abbott’s Libre gets pump integration
- DexCom down more than 7% after FDA gives nod to Abbott CGM sensors